Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544071 | 1.00 | MAT2A (0.32) | MAT2AHTTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL543896 | 0.78 | SMN1; SMN2 (0.36) | MAT2AHTTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL22573203 | 0.71 | ALDH1A1 (0.38) | HTTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL6118775 | 0.69 | ALDH1A1 (0.41) | HTTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL17682469 | 0.69 | AR (0.39) | MAT2AHTTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL29303418 | 0.69 | TSHR (0.43) | HTTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL26156069 | 0.69 | CYP1A2 (0.37) | MAT2AHTTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL24743746 | 0.67 | MPO (0.40) | MAT2AKDM4EALDH1A1HPGDTSHR | |
| SCHEMBL27780630 | 0.67 | FGFR1 (0.39) | SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL543413 | 0.67 | ATM (0.41) | MAT2AHTTSMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2141150-B1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-8110585-B2 | Bicyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-27 | — | — | US | disclosed |
| EP-2141150-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, XDH | MAT2A 654/4885HTT 473/4885SMN1; SMN2 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.